Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Kátia Nones

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1925-5196; OpenAlex author ID A5085661408. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 13

  1. Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification. Co-author DOI 10.1158/2767-9764.crc-25-0229↗
  2. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  3. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  4. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  5. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Last author DOI 10.1016/j.celrep.2020.107625↗
  6. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  7. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  8. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗
  9. Whole genomes redefine the mutational landscape of pancreatic cancer. Co-author DOI 10.1038/nature14169↗
  10. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Co-author DOI 10.1002/ijc.28765↗
  11. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Co-author DOI 10.1186/gm482↗
  12. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Co-author DOI 10.1038/nature11547↗
  13. RON is not a prognostic marker for resectable pancreatic cancer. Co-author DOI 10.1186/1471-2407-12-395↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sean Michael Grimmond · 3 shared papers, 2012–2014 · strength 0.08
  2. Anthony James Gill · 3 shared papers, 2012–2014 · strength 0.08
  3. Mark J. Cowley · 3 shared papers, 2012–2014 · strength 0.08
  4. David Kuang-Fu Chang · 3 shared papers, 2012–2014 · strength 0.08
  5. Andrew Victor Biankin · 3 shared papers, 2012–2014 · strength 0.08
  6. Angela S. Y. Chou · 2 shared papers, 2012–2013 · strength 0.05
  7. Amber L. Johns · 2 shared papers, 2013–2014 · strength 0.05
  8. Marina Pajic · 2 shared papers, 2013–2014 · strength 0.05
  9. Ilse Rooman · 2 shared papers, 2013–2014 · strength 0.05
  10. Carole M. Tactacan · 1 shared paper, 2012 · strength 0.03
  11. Emily S. Humphrey · 1 shared paper, 2012 · strength 0.03
  12. Roger J. Daly · 1 shared paper, 2012 · strength 0.03
  13. and Australian Pancreratic Genome Initiative · 1 shared paper, 2012 · strength 0.03
  14. Peter J. Bailey · 1 shared paper, 2014 · strength 0.03
  15. Vincenzo Corbo · 1 shared paper, 2014 · strength 0.03
  16. Giovanni Butturini · 1 shared paper, 2014 · strength 0.03
  17. Rita Teresa Lawlor · 1 shared paper, 2014 · strength 0.03
  18. Massimo Falconi · 1 shared paper, 2014 · strength 0.03
  19. Stefano Crippa · 1 shared paper, 2014 · strength 0.03
  20. Aldo Scarpa Scarpa · 1 shared paper, 2014 · strength 0.03
  21. Jeremy L. Humphris · 1 shared paper, 2013 · strength 0.02
  22. David Goldstein · 1 shared paper, 2013 · strength 0.02
  23. Jaswinder Singh Samra · 1 shared paper, 2013 · strength 0.02
  24. Venessa T. Chin · 1 shared paper, 2013 · strength 0.02
  25. Lorraine A. Chantrill · 1 shared paper, 2013 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.